Appili therapeutics presents update on ati-1701 biodefense vaccine candidate at idweek™ 2024

Ati-1701 provides full protection against lethal tularemia in animal models after one year company to provide update on tularemia vaccine candidate ati-1701 and present new data on efficacy presentation scheduled for 3:15 pm et on october 17, 2024 halifax, nova scotia, oct. 17, 2024 (globe newswire) -- appili therapeutics inc. (tsx: apli; otcpink: aplif) (the “company” or “appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that gary nabors, ph.d., chief development officer, and key members of appili's scientific team, will participate at idweek 2024™, and present an update on the appili biodefense program ati-1701.
ATI Ratings Summary
ATI Quant Ranking